title: Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome.
abstract: As the terminal differentiation products of human urothelium, uroplakins (UPs) would be expected to diminish during urothelial tumorigenesis. Surprisingly, recent studies found UPs to be retained even by well-advanced urothelial carcinomas, suggesting that the loss of UPs does not strictly parallel urothelial transformation. Little is known, however, about whether the status of UPs is associated with a particular pathologic parameter, the tumor's biological behavior, or patient outcome. Here we assessed UP expression by immunohistochemistry on tissue arrays from 285 patients with bladder urothelial carcinomas or nontumor conditions. UPs were expressed in all 9 normal urothelial specimens, 63 of 74 (85%) patients with non-muscle-invasive urothelial carcinomas on transurethral resection, 104 of 202 (51.5%) patients who underwent radical cystectomy for advanced urothelial carcinomas, and 33 of 50 (66%) lymph node metastases. Normally associated with urothelial apical surface, UPs were localized aberrantly in tumors, including microluminal, basal-laminal, cytoplasmic, or uniform patterns. In non-muscle-invasive diseases, there was no association between UP expression and disease recurrence, progression, or mortality. In contrast, in invasive diseases, absent UP expression was significantly associated with advanced pathologic stage, lymph node metastases, disease recurrence, and bladder cancer-specific mortality (P = .042, P = .035, P = .023, and P = .022, respectively) in univariate analyses. Furthermore, UP status was independent of key cell-cycle regulators, including p53, pRb, p27, and cyclin D1, thus excluding a functional link between these 2 groups of proteins. Our data demonstrate for the first time that persistent UP expression is associated with a favorable clinical outcome and that UPs may be used as adjunct markers for predicting the prognoses of patients with invasive and metastatic bladder carcinomas. Our results also suggest that UP-positive and -negative carcinomas have different clonal origins or may be derived from different cancer stem cells.
authors: Department of Urology, NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA.
authors: Hong-Ying
authors: HY
authors: Huang
authors: Shahrokh F
authors: SF
authors: Shariat
authors: Tung-Tien
authors: TT
authors: Sun
authors: Herbert
authors: H
authors: Lepor
authors: Ellen
authors: E
authors: Shapiro
authors: Jer-Tsong
authors: JT
authors: Hsieh
authors: Raheela
authors: R
authors: Ashfaq
authors: Yair
authors: Y
authors: Lotan
authors: Xue-Ru
authors: XR
authors: Wu
mesh_terms: D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000503:physiopathology; D014565:Urogenital Neoplasms / Q000473:pathology* / Q000503:physiopathology*; D019459:Urothelium / Q000378:metabolism*
chemical_list: D008562:Membrane Glycoproteins
references: J Pathol. 2003 Jan;199(1):41-9
references: 12474225
references: J Cell Biol. 2002 Nov 25;159(4):685-94
references: 12446744
references: Am J Surg Pathol. 2003 Jan;27(1):1-10
references: 12502922
references: Toxicol Pathol. 2002 Nov-Dec;30(6):663-71
references: 12512866
references: Urol Oncol. 2003 Nov-Dec;21(6):475-8
references: 14693276
references: Urol Oncol. 2004 Mar-Apr;22(2):86-92
references: 15082003
references: Adv Exp Med Biol. 2003;539(Pt A):33-46
references: 15088894
references: Cancer Cell. 2004 Aug;6(2):111-6
references: 15324694
references: J Cell Biol. 1965 Jul;26(1):25-48
references: 5859020
references: Lab Invest. 1969 Aug;21(2):154-68
references: 5804627
references: Cancer Res. 1977 Aug;37(8 Pt 2):2824-35
references: 326393
references: J Natl Cancer Inst. 1993 Feb 3;85(3):200-6
references: 8423624
references: Lancet. 1993 Aug 21;342(8869):469-71
references: 8102431
references: J Biol Chem. 1994 May 6;269(18):13716-24
references: 8175808
references: Am J Pathol. 1995 Nov;147(5):1383-97
references: 7485401
references: J Biol Chem. 1995 Dec 15;270(50):29752-9
references: 8530366
references: Eur Urol. 1998;33 Suppl 4:2-4
references: 9615195
references: Am J Pathol. 1998 Dec;153(6):1957-67
references: 9846985
references: Urol Int. 2004;73(3):201-8
references: 15539837
references: Clin Cancer Res. 2005 May 15;11(10):3773-7
references: 15897575
references: Nat Rev Cancer. 2005 Sep;5(9):713-25
references: 16110317
references: J Clin Oncol. 2005 Sep 20;23(27):6533-9
references: 16116151
references: Nat Rev Cancer. 2005 Nov;5(11):899-904
references: 16327766
references: Neoplasia. 2005 Dec;7(12):1091-103
references: 16354592
references: Urology. 2005 Dec;66(6 Suppl 1):64-74
references: 16399416
references: Arch Pathol Lab Med. 2006 Jun;130(6):844-52
references: 16740038
references: Am J Physiol Renal Physiol. 2006 Jul;291(1):F9-21
references: 16609152
references: Hum Pathol. 2006 Dec;37(12):1568-76
references: 16949911
references: J Cell Biol. 2000 Nov 27;151(5):961-72
references: 11085999
references: Clin Cancer Res. 2001 Jun;7(6):1516-22
references: 11410485
references: Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7
references: 11584300
references: Int J Cancer. 2001 Oct 15;94(2):153-6
references: 11668491
references: Mol Biol Cell. 2002 Mar;13(3):830-46
references: 11907265
references: Am J Med Genet. 2002 Oct 30;115(3):173-82
references: 12407698
references: Mol Biol Cell. 2002 Dec;13(12):4221-30
references: 12475947